Physician profile
Gary Sterba
NPI 1942504832
$2,682.43
in general payments reported to CMS, 2019-2025
14 companies · $552 in 2025
The $552 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $131 · 2021: $16.55 · 2022: $368 · 2023: $411 · 2024: $681 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,637 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,636.89 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $689.30 | 2023-2025 | Purified Cortrophin Gel |
| Astrazeneca Uk Limited | $395.62 | 2019 | |
| Mallinckrodt Hospital Products INC. | $264.33 | 2022-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $243.64 | 2024-2025 | Lupkynis |
| Abbvie INC. | $243.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $217.25 | 2022-2024 | Saphnelo |
| Lilly USA, LLC | $157.58 | 2022 | |
| Genzyme Corporation | $147.61 | 2023 | |
| Glaxosmithkline, LLC. | $147.07 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.74 | 2023-2025 | Ofev |
| Amgen INC. | $50.87 | 2021-2024 | Enbrel |
| Radius Health, INC. | $16.79 | 2023 | Tymlos |
| Gilead Sciences, INC. | $16.57 | 2020 | |
| Pfizer INC. | $15.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Sterba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.